MARKET

MIRM

MIRM

Mirum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.98
-0.18
-0.75%
Opening 14:56 12/04 EST
OPEN
24.10
PREV CLOSE
24.16
HIGH
24.68
LOW
23.57
VOLUME
53.88K
TURNOVER
--
52 WEEK HIGH
28.31
52 WEEK LOW
7.92
MARKET CAP
616.69M
P/E (TTM)
-7.0000
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mirum Pharma maralixibat application for rare liver disorder accepted in Europe
The European Medicines Agency ((EMA)) accepts for review Mirum Pharmaceuticals' ([[MIRM]] +5.0%) marketing application seeking approval of maralixibat for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2), a
Seekingalpha · 4d ago
Mirum Pharmaceuticals Announces European Medicines Agency Validation Of The Marketing Authorization Application For Maralixibat In Patients With PFIC2
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2 - Five-year transplant-free survival data from the Phase 2
Benzinga · 4d ago
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2
Business Wire · 4d ago
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2
Business Wire · 4d ago
Mirum Pharmaceuticals Announced Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced data presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting Digital Experience™. The data were presented by Dr.
Benzinga · 11/16 10:50
Mirum Pharmaceuticals Highlights Presentation Of Data From Its Maralixibat And Volixibat Clinical Studies At AASLD Annual Meeting
Maralixibat data highlights the relationship between the reduction of serum bile acids and pruritus intensity, improved growth, and other quality of life measures. Analysis of the natural variability of pruritus in
Benzinga · 11/13 13:12
Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting
Mirum Pharmaceuticals Presents New Data From its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting
Business Wire · 11/13 13:10
Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $52
Raymond James maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and raises the price target from $48 to $52.
Benzinga · 11/13 12:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MIRM. Analyze the recent business situations of Mirum Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MIRM stock price target is 49.29 with a high estimate of 77.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 70
Institutional Holdings: 18.90M
% Owned: 73.50%
Shares Outstanding: 25.72M
TypeInstitutionsShares
Increased
20
453.27K
New
9
-139.78K
Decreased
19
390.47K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.32%
Pharmaceuticals & Medical Research
+1.32%
Key Executives
Chairman/Director
Michael Grey
President/Chief Executive Officer/Director
Christopher Peetz
Chief Financial Officer
Ian Clements
Chief Scientific Officer
Pamela Vig
Other
Lara Longpre
Other
Edwin Tucker
Director
Tiba Aynechi
Independent Director
Laura Brege
Independent Director
Laurent Fischer
Independent Director
Patrick Heron
Independent Director
Edward Mathers
Independent Director
Niall ODonnell
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a range of orphan liver diseases. The Company initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. It has commenced enrollment in the Phase III clinical trial in PFIC and also planning to initiate a Phase III clinical trial in ALGS. The Company is developing volixibat for the treatment of adult patients with cholestatic liver diseases and expect to initiate Phase II clinical trials. In addition to data from ongoing clinical trials of maralixibat.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Mirum Pharmaceuticals Inc stock information, including NASDAQ:MIRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MIRM stock methods without spending real money on the virtual paper trading platform.